AI assistant
4D Molecular Therapeutics, Inc. — Director's Dealing 2021
Oct 23, 2021
33060_dirs_2021-10-22_050ff761-e3fc-44f5-8461-413cd4097cd5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: 4D Molecular Therapeutics Inc. (FDMT)
CIK: 0001650648
Period of Report: 2021-10-20
Reporting Person: SCHAFFER DAVID (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-10-20 | Common Stock | S | 11565 | $31.0221 | Disposed | 925935 | Direct |
| 2021-10-21 | Common Stock | S | 22820 | $31.5581 | Disposed | 903115 | Direct |
| 2021-10-22 | Common Stock | S | 1900 | $30.9962 | Disposed | 901215 | Direct |
Footnotes
F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2: The transaction was executed in multiple trades in prices ranging from $30.27 to $32.07,inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: The transaction was executed in multiple trades in prices ranging from $30.70 to $32.39, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4: The transaction was executed in multiple trades in prices ranging from $30.76 to $31.66, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.